# Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant

> **NCT04044560** · PHASE2 · TERMINATED · sponsor: **University of British Columbia** · enrollment: 8 (actual)

## Conditions studied

- B-cell Adult Acute Lymphoblastic Leukemia
- Stem Cell Leukemia
- Minimal Residual Disease

## Interventions

- **BIOLOGICAL:** blinatumomab

## Key facts

- **NCT ID:** NCT04044560
- **Lead sponsor:** University of British Columbia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-08
- **Primary completion:** 2022-02-02
- **Final completion:** 2022-02-02
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Slow enrolment, loss of funding
- **Last updated:** 2022-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04044560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04044560, "Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04044560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*